PR Newswire Clinical TrialsOriginal article
Cumulus Neuroscience präsentiert auf der AAIC-Jahrestagung 2026 Daten, die zeigen, dass eine zweiminütige digitale Aufgabe die klinischen Referenzwerte für die Vorauswahl bei Alzheimer-Studien erreicht oder übertrifft
ConferencepositiveNeuLogiqPositive
AI Analysis
Summary
Cumulus Neuroscience presented data at AAIC 2026 demonstrating that a two-minute tablet-based digital task (Symbol Swap) from its NeuLogiq platform achieves clinical reference standards for distinguishing between healthy controls, mild cognitive impairment, and Alzheimer's dementia patients across three independent studies.
Clinical Trial Data
Primary Endpoint
Met
Outcome Details
Two-minute digital Symbol Swap task demonstrated clinically meaningful discrimination between controls, MCI, and Alzheimer's dementia patients, meeting clinical reference standards for pre-screening in Alzheimer's studies
Importance:6/10
Sentiment:
0.75
Alzheimer's diseasedigital biomarkerdiagnostic toolAAIC 2026cognitive assessmentblood biomarkers
Read the original article
Published by PR Newswire Clinical Trials on July 16, 2026 7:22 AM